SCHEMBL4790307

SCHEMBL4790307

COC(=O)CC1CCN(C(=O)OCCCCNc2ccccn2)Cc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 11/20 0.44
ITGAV P06756 11/20 0.44
ITGA2B P08514 7/20 0.44
ITGB5 P18084 4/20 0.44
ITGB1 P05556 2/20 0.44
NOS2 P35228 1/20 0.44
GRIN2B Q13224 2/20 0.42
ADRA1A P35348 2/20 0.39
F2 P00734 1/20 0.37
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
NAMPT P43490 1/20 0.37
DPP4 P27487 1/20 0.36
HTR1A P08908 1/20 0.35
HTR1D P28221 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4760395 0.91 ITGB3 (0.53) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4760965 0.86 NAMPT (0.45) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4789373 0.84 DPP4 (0.48) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4790911 0.82 NAMPT (0.49) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4791396 0.81 ITGB3 (0.44) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4714941 0.78 GRIN2B (0.39) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4760017 0.78 ITGB3 (0.54) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4762157 0.77 ITGB3 (0.51) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4762284 0.77 ITGB3 (0.53) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4720020 0.77 ITGB3 (0.46) ITGB3ITGAVITGA2BITGB5ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed